Black Rock Inc. Vaxcyte, Inc. Transaction History
Black Rock Inc.
- $4.35 Trillion
- Q2 2024
A detailed history of Black Rock Inc. transactions in Vaxcyte, Inc. stock. As of the latest transaction made, Black Rock Inc. holds 9,939,846 shares of PCVX stock, worth $323 Million. This represents 0.02% of its overall portfolio holdings.
Number of Shares
9,939,846
Previous 9,513,007
4.49%
Holding current value
$323 Million
Previous $650 Million
15.5%
% of portfolio
0.02%
Previous 0.02%
Shares
13 transactions
Others Institutions Holding PCVX
# of Institutions
345Shares Held
136MCall Options Held
348KPut Options Held
250K-
Ra Capital Management, L.P. Boston, MA12.2MShares$396 Million9.56% of portfolio
-
Vanguard Group Inc Valley Forge, PA12MShares$391 Million0.01% of portfolio
-
Janus Henderson Group PLC London, X011.8MShares$382 Million0.25% of portfolio
-
Wellington Management Group LLP Boston, MA6.42MShares$208 Million0.05% of portfolio
-
Capital Research Global Investors Los Angeles, CA6.11MShares$199 Million0.05% of portfolio
About Vaxcyte, Inc.
- Ticker PCVX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 59,315,100
- Market Cap $1.93B
- Description
- Vaxcyte, Inc., a clinical-stage biotechnology vaccine company, develops novel protein vaccines to prevent or treat bacterial infectious diseases. Its lead vaccine candidate is VAX-24, a 24-valent investigational pneumococcal conjugate vaccine that is in Phase 1/2 clinical trials to treat invasive pneumococcal disease and pneumonia. The company a...